---
title: "Claseprubart (DNTH103) in Generalized myasthenia gravis: Natural history, survival, and mortality"
description: "Formulary evidence on Claseprubart (DNTH103) in Generalized myasthenia gravis: Natural history, survival, and mortality. Topics: Natural history: progression from ocular to generalized disease; Natural history: severity peaks early, and exacerbations recur; Natural history: spontaneous remission; Mortality: global systematic review; 7 further topics. 11 evidence topics quoted from 14 sources."
canonical: "https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/product-information-and-disease-description/natural-history-survival-and-mortality"
published: "2026-11-15T22:20:57-05:00"
modified: "2026-11-15T22:20:57-05:00"
---

# Claseprubart (DNTH103) in Generalized myasthenia gravis: Natural history, survival, and mortality

<a id="heading-2.2.1.3"></a>

## 2.2.1.3 Natural History, Survival, and Mortality

<a id="topic-2.2.1.3-1"></a>

### Natural history: progression from ocular to generalized disease

> “In addition, up to 80% of patients with ocular onset will go on to develop generalized symptoms, usually within two years of disease onset”
> “A recent population-based study conducted by the Mayo Clinic found that 51% of patients presented with ocular onset, and 55% of these developed generalized symptoms”
> “Of the remaining, 90% will continue to have ocular manifestations only.”
> “Hence, ocular MG is defined by isolated extra-ocular involvement for a period of ≥2 years.”

Source: [Dresser et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8196750/)

> “Most patients initially present with ocular symptoms, however approximately 80% progress to generalized disease”

Source: [Barnett-Tapia et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13498700/)

<a id="topic-2.2.1.3-2"></a>

### Natural history: severity peaks early, and exacerbations recur

> “Between 1940 and 2000 a total of 1976 patients with myasthenia gravis (MG) were studied.”
> “The most severe level of weakness and high mortality occurred during the first 1 to 2 years of the disease, after which many patients experienced improvement.”

Source: [Grob et al. (2008)](https://pubmed.ncbi.nlm.nih.gov/18059039/)

> “Most patients with MG will experience at least 1 exacerbation of symptoms throughout the course of their illness.”

Source: [Hehir and Silvestri (2018)](https://pubmed.ncbi.nlm.nih.gov/29655448/)

> “Within any given year, approximately one third of patients with gMG experience myasthenic exacerbations (MEs), which are periods when muscle weakness worsens beyond the patient's usual symptoms level”

Source: [Grover et al. (2026b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13724412/)

<a id="topic-2.2.1.3-3"></a>

### Natural history: spontaneous remission

> “Spontaneous remissions for different lengths of time may occur in the course of adult-onset MG.”
> “In an earlier study conducted before the widespread use of steroids and other immunosuppressants, approximately one fourth of the patients had a complete or near complete spontaneous remission, lasting an average of 4.6 years and up to 17 years”
> “Half of the remissions occurred during the first year after onset.”

Source: [Dresser et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8196750/)

<a id="topic-2.2.1.3-4"></a>

### Mortality: global systematic review

> “showing a mean MR of 1.4 (95% CI: 0.8–2.1; range: 0.5–3.5) cases per million person-years.”
> “No trend was observed for MR over the years”

Source: [Sciancalepore et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12500283/)

> “MR range 0.1 to 0.9 per millions person-years.”

Source: [Carr et al. (2010)](https://pmc.ncbi.nlm.nih.gov/articles/PMC2905354/)

<a id="topic-2.2.1.3-5"></a>

### Mortality: United States hospitalizations, 2010 to 2019

> “Readmission rates were approximately 20% in each study year for both crisis and noncrisis hospitalizations; the in-hospital mortality rate averaged 1.8%.”
> “Mortality among patients aged 65 years or older was higher compared with that in all patients, averaging 5.0% across each of the study years.”

Source: [Habib et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/38165317/)

<a id="topic-2.2.1.3-6"></a>

### Mortality: United States hospitalizations, 2000 to 2005

> “The overall in-hospital mortality rate was 2.2%, being higher in MG crisis (4.47%).”
> “Older age and respiratory failure were the predictors of death, with adjusted odds ratios of 9.28 (95% confidence interval [CI], 3.31, 26.0) and 3.58 (95% CI, 2.01, 6.38).”

Source: [Alshekhlee et al. (2009)](https://pubmed.ncbi.nlm.nih.gov/19414721/)

<a id="topic-2.2.1.3-7"></a>

### Mortality and survival: United States Medicare beneficiaries aged 65 years and older

> “All-cause mortality among MG beneficiaries was stable from 6.26 deaths per 100 PYs in 2006–2007 to 5.67 in 2018–2019 (p = 0.18).”

Source: [Bruckman et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11540456/)

> “Cohorts of 6024 incident MG and 30,083 control beneficiaries were Included.”
> “The mortality rate was higher in the MG cohort compared to controls (66.8 vs. 57.1 per 1000-person-year, p < 0.0001).”
> “After adjusting for time-varying CCI, no significant difference in survival was observed between two cohorts (adjusted hazard ratio 1.09 [0.87-1.36], p = 0.47).”
> “Sixteen percent of deaths in the MG cohort were attributed to MG.”
> “Compared to the non-MG cohort, mortality rates (per 1000-person-year) specific to infections were higher among the MG cohort (2.0 vs. 1.2) while malignancies and dementia-specific mortality rates were lower (10.3 vs. 12.5 and 4.7 vs. 7.2), all p < 0.01.”

Source: [Li et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/41104507/)

<a id="topic-2.2.1.3-8"></a>

### Mortality: Denmark nationwide cohort, 1985 to 2020

> “Our cohort encompassed 2,110 patients (50.2% female) and 21,100 from the general population, with 77.3% aged younger than 75 years.”
> “Short-term cumulative mortality was 4.8% in patients with MG and 2.6% in the general population, yielding a HR of 1.8 (95% CI 1.5-2.3). Long-term mortality was 1.3 (95% CI 1.1-1.5).”
> “Comorbidity-adjusted analyses decreased short-term mortality (HR 1.6, 95% CI 1.3-2.0), and long-term mortality aligned with the general population.”

Source: [Jul Jarbæk Nielsen et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/40460351/)

<a id="topic-2.2.1.3-9"></a>

### Mortality: Taiwan, generalized myasthenia gravis, 2009 to 2019

> “The all-cause fatality rate ranged from 2.76 to 3.79 per 100 patients in each study year, with no consistent temporal trend observed.”

Source: [Herr et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10327564/)

<a id="topic-2.2.1.3-10"></a>

### Survival: Ontario, Canada, with and without myasthenic crisis

> “Myasthenic crisis occurred in 8.9% of individuals over the study, with a post‐diagnosis incidence rate of 2.6 per 100 person‐years and 30‐day mortality of 28.1%.”
> “5‐year overall survival was 75%, declining to 39% among those with crisis.”

Source: [Barnett-Tapia et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13498700/)

<a id="topic-2.2.1.3-11"></a>

### Mortality: Israel, tertiary center cohort, 2000 to 2023

> “Myasthenia Gravis mortality was 14% at 5 years (61/422) and 21% at 10 years (87/422).”
> “Mortality was significantly higher than control groups (p < 0.001).”
> “Intubations during myasthenic crisis were linked to higher mortality (p = 0.002).”

Source: [Khateb et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12116355/)

## Related pages
- [Claseprubart (DNTH103): Generalized myasthenia gravis](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis) · [Markdown](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis.md)
- [Claseprubart (DNTH103) in Generalized myasthenia gravis: Terms and abbreviations](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/terms-and-abbreviations.md)
- [Claseprubart (DNTH103): Generalized myasthenia gravis](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/executive-summary) · [Markdown](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/executive-summary.md)
- [Claseprubart (DNTH103) in Generalized myasthenia gravis: Product information and disease description](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/product-information-and-disease-description.md)
- [Claseprubart (DNTH103) in Generalized myasthenia gravis: Clinical evidence](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/clinical-evidence.md)
- [Claseprubart (DNTH103) in Generalized myasthenia gravis: Economic information and modeling report](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/economics) · [Markdown](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/economics.md)
- [Claseprubart (DNTH103) in Generalized myasthenia gravis: References](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/references) · [Markdown](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/references.md)
